IL17A and inflammatory bowel disease: As a whole, these modulatory effects give an insight on the novel therapeutic role of probiotics in alleviating IBD via suppression of the costimulatory molecules in IECs such as CD80/CD86 and CD40, which are vital in activating expression of IL-17A during IBD pathogenesis.